John Libbey Eurotext

Journal de Pharmacie Clinique


5-fluorouracil safety in patients with dihydropyrimidine dehydrogenase deficiency Volume 32, issue 3, Septembre 2013


See all figures

Service pharmacie, Centre hospitalier régional universitaire de Brest, France, Institut de cancérologie et hématologie, Centre hospitalier régional universitaire de Brest, France
  • Key words: 5-fluorouracil, capecitabine, dihydropyrimidine dehydrogenase, chemotherapy, toxicity
  • DOI : 10.1684/jpc.2013.0257
  • Page(s) : 154-60
  • Published in: 2013

5-fluorouracil (5-FU) is the cornerstone of the treatment of digestive cancers. Its catabolism and deactivation mostly depend on dihydropyrimidine dehydrogenase (DPD). Patients with DPD deficiency are at high risk of 5-FU early related side effects. Our objective was to assess the safety of 5-FU in patients with DPD deficiency considering a pharmacokinetic approach by the oncopharmacogenetics laboratory. Material and methods: we retrospectively analysed the files of patients who had DPD deficiency. DPD deficiency was diagnosed by the oncopharmacogenetics laboratory considering a multiparametric analyse. 5-FU dosage adjustments were also suggested by this laboratory by calculating 5-FU plasma clearance after the first 5-FU infusion. 5-FU dosage suggested by the laboratory and the 5-FU dosage really prescribed were compared for each patient and each chemotherapy cycle. Clinical and biological treatment safety data were collected. Results: we were able to analyse the files of 11 patients. Patients were mostly treated for colorectal cancers in adjuvant or metastatic situation. 5-FU dosage bolus and continuous infusion were consistent with laboratory suggestions in, respectively, 84% and 53% of cases. Two patients experienced haematological toxicity, respectively grade 3 and grade 4 which lead to permanently stop 5-FU. For those two patients DPD deficiency had not been searched prior to prescribing 5-FU. Conclusion: this study showed that 5-FU was well tolerated in patients DPD deficiency provided clinicians adjusted 5-FU dosage. Our results showed that a pharmacokinetics approach was useful for preventing 5-FU side effects in patients with DPD deficiency.